The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee held its long-awaited meetings this week to decide whether to advise the FDA to raise the standards for approving diabetes drugs. With questions being raised about the benefits versus risks for other long-term drugs, such as treatments for cholesterol, mental illness and anemia, all facing similar scrutiny, the FDA’s final decision
